Arrow Generiques SAS to acquire select commercial products in France from TevaArrow Generiques SAS, the French subsidiary of Aurobindo Pharma, announced the signing of an agreement to acquire select commercial products in France from Teva. Arrow Generiques will acquire the right, title and interest in products Calcium and Calcium Vitamin D3, including the use of the OROCAL trademark.
The transaction is subject to the approval of the European Commission. Following receipt of clearances from European authorities, Arrow Generiques will integrate these products with its existing commercial operations in France, and focus on maximizing their potential.
Arrow Generiques and Teva intend to ensure continuity of the supply of the products to the market.
This acquisition will enable Arrow Generiques to continue to increase its branded products portfolio and leverage its position as a key player in the drug market. Arrow Generiques is a pharmaceutical company with focus on selling generics on the retail and hospital markets in France since 2002. Arrow Generiques entered a strategy of diversification with the acquisition of the first branded products a few years ago to become a company balanced between generics / branded products / biosimilars on retail and hospital market. A dedicated Business Unit with sales and marketing team had been set up to specifically enhance this business.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)